Here we use a combination of functional approaches to demonstrate that loss of PALB2 or BARD1 is sufficient to confer an HR-deficient phenotype and drive PARP inhibitor sensitivity in prostate cancer models. Here, PALB2 is linked to prostate carcinoma.